DK1250926T3 - Anvendelse af vanduoplöseligt S-camptothecin med en lukket lactonring i fremstilling af et medikament til behandling af coloncancer - Google Patents

Anvendelse af vanduoplöseligt S-camptothecin med en lukket lactonring i fremstilling af et medikament til behandling af coloncancer

Info

Publication number
DK1250926T3
DK1250926T3 DK02015200T DK02015200T DK1250926T3 DK 1250926 T3 DK1250926 T3 DK 1250926T3 DK 02015200 T DK02015200 T DK 02015200T DK 02015200 T DK02015200 T DK 02015200T DK 1250926 T3 DK1250926 T3 DK 1250926T3
Authority
DK
Denmark
Prior art keywords
camptothecin
treatment
insoluble
water
colon cancer
Prior art date
Application number
DK02015200T
Other languages
Danish (da)
English (en)
Inventor
Beppino C Giovanella
Hellmuth R Hinz
Anthony J Kozielski
John S Stehlin
Original Assignee
Stehlin Foundation For Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stehlin Foundation For Cancer filed Critical Stehlin Foundation For Cancer
Application granted granted Critical
Publication of DK1250926T3 publication Critical patent/DK1250926T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK02015200T 1993-01-15 1994-01-14 Anvendelse af vanduoplöseligt S-camptothecin med en lukket lactonring i fremstilling af et medikament til behandling af coloncancer DK1250926T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US284493A 1993-01-15 1993-01-15
PCT/US1994/000403 WO1994015604A1 (fr) 1993-01-15 1994-01-14 Traitement transdermique du cancer au moyen de s-camptothecine insoluble dans l'eau de la forme fermee du cycle de lactone

Publications (1)

Publication Number Publication Date
DK1250926T3 true DK1250926T3 (da) 2008-07-07

Family

ID=21702794

Family Applications (3)

Application Number Title Priority Date Filing Date
DK97101631T DK0778024T3 (da) 1993-01-15 1994-01-14 Oral eller intramuskulær behandling af pancreascancer med vanduopløselig S-camptothecin i lukket lactonring-formen
DK94907804T DK0678025T3 (da) 1993-01-15 1994-01-14 Transdermal behandling af cancer med vand-ouopløslig S-camptothecin af den lukkede lactonringform
DK02015200T DK1250926T3 (da) 1993-01-15 1994-01-14 Anvendelse af vanduoplöseligt S-camptothecin med en lukket lactonring i fremstilling af et medikament til behandling af coloncancer

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK97101631T DK0778024T3 (da) 1993-01-15 1994-01-14 Oral eller intramuskulær behandling af pancreascancer med vanduopløselig S-camptothecin i lukket lactonring-formen
DK94907804T DK0678025T3 (da) 1993-01-15 1994-01-14 Transdermal behandling af cancer med vand-ouopløslig S-camptothecin af den lukkede lactonringform

Country Status (9)

Country Link
EP (3) EP1250926B1 (fr)
JP (1) JP3099128B2 (fr)
AT (3) ATE388706T1 (fr)
CA (1) CA2148822C (fr)
DE (3) DE69409633T2 (fr)
DK (3) DK0778024T3 (fr)
ES (3) ES2114681T3 (fr)
PT (1) PT1250926E (fr)
WO (1) WO1994015604A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244903A (en) * 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
ES2165346T3 (es) * 1989-09-15 2002-03-16 Res Triangle Inst Analogos de 10,11-metilendioxi-20(rs)-camptotecina y 10,11-metilendioxi-20(s)-camptotecina.
US5422344A (en) * 1990-05-08 1995-06-06 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Method of treating retroviral infections in mammals
EP0540099B1 (fr) * 1991-10-29 1996-04-17 Glaxo Wellcome Inc. Dérivés de camptothécine solubles dans l'eau
ATE247471T1 (de) * 1991-11-15 2003-09-15 Smithkline Beecham Corp Cisplatin und topotecan enthaltende zusammensetzung als antitumor.
JPH07501818A (ja) * 1991-12-10 1995-02-23 スミスクライン・ビーチャム・コーポレイション 結腸直腸癌の治療

Also Published As

Publication number Publication date
EP0778024B1 (fr) 2002-11-13
ATE165003T1 (de) 1998-05-15
DE69409633T2 (de) 1998-08-06
ATE227573T1 (de) 2002-11-15
JPH08505626A (ja) 1996-06-18
DE69435084T2 (de) 2009-03-19
ATE388706T1 (de) 2008-03-15
EP1250926A3 (fr) 2002-11-20
WO1994015604A1 (fr) 1994-07-21
EP0778024A1 (fr) 1997-06-11
JP3099128B2 (ja) 2000-10-16
DK0778024T3 (da) 2002-12-23
DE69409633D1 (de) 1998-05-20
DK0678025T3 (da) 1998-10-07
CA2148822A1 (fr) 1994-07-21
PT1250926E (pt) 2008-06-11
EP1250926A2 (fr) 2002-10-23
ES2114681T3 (es) 1998-06-01
EP1250926B1 (fr) 2008-03-12
ES2186812T3 (es) 2003-05-16
CA2148822C (fr) 2001-03-27
DE69431731D1 (de) 2002-12-19
DE69431731T2 (de) 2003-03-13
DE69435084D1 (de) 2008-04-24
ES2301590T3 (es) 2008-07-01
EP0678025B1 (fr) 1998-04-15
EP0678025A1 (fr) 1995-10-25

Similar Documents

Publication Publication Date Title
DK203787A (da) Praeparat til nasal administrering
DK0449247T3 (da) Farmaceutisk formulering indeholdende galanthamin til behandling af alkoholisme
DK0831827T3 (da) Nye formuleringer til transdermal levering af pergolid
DE3779500D1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
ATE151637T1 (de) Heterozyklische verbindungen
DK541189D0 (da) Anvendelse af nalmefen eller naltrexon til fremstilling af et laegemiddel til behandling af interstitiel cystitis
DK598288D0 (da) Vaeskeformig farmaceutisk sammensaetning til behandling af hoste og oemhed i halsen
DK1250926T3 (da) Anvendelse af vanduoplöseligt S-camptothecin med en lukket lactonring i fremstilling af et medikament til behandling af coloncancer
DE69233773D1 (de) Verwendung von topotecan zur herstellung eines medikaments zur verwendung in der behandlung von ovarialkrebs
DE60130253D1 (de) Zusammensetzungen zur verhinderung der adhäsion
GB9202993D0 (en) Novel pharmaceutical uses of bilobalide and derivatives thereof and pharmaceutical compositions adapted for such use
DK0457336T3 (da) Ny anvendelse af 4-carbamoyl-1-beta-D-ribofuranosylimidazolium-5-olat
SE8107833L (sv) Substituerade tetrahydro-1,2,4-oxadiazin-5-on-derivat med kramplosande verkan, sett for deras framstellning och farmaceutiska beredningar innehallandedem
DE3683550D1 (de) Verwendung eines quinazolinons zur herstellung eines arzneimittels gegen vertigo und pharmazeutische zusammensetzung.